Clinical trials: Women With Breast Cancer
Ovarian Neoplasms, Breast Neoplasms
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
To determine the safety and immunogenicity profile of two (2) different doses of the vaccine DPX-0907 to treat breast, ovarian and prostate cancer.
- Conditions
- Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
- Trial name
- NCT01095848
- Testing
- DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
Local Neoplasm Recurrence, Distantly Metastatic Malignant Neoplasm
Partial Breast Versus no Irradiation for Women With Early Breast Cancer
All early breast cancer patients are offered adjuvant breast radiation therapy (RT) after breast conserving surgery for an early breast cancer.
- Conditions
- Local Neoplasm Recurrence, Distantly Metastatic Malignant Neoplasm, Death, Fibrosis Breast
- Trial name
- NCT03646955
- Testing
- No partial breast irradiation
- Where
- 17 sites in Chile, Denmark and 2 more
- Volunteers
- 926 people
- Sponsor
- Danish Breast Cancer Cooperative Group
Recurrent Ovarian Cancer, HER2-negative
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 Combination Treatment in subjects with advanced solid tumors.
- Conditions
- Recurrent Ovarian Cancer, HER2-negative, Advanced Breast Cancer, TNBC
- Trial name
- HS-10502 (NCT06769425)
- Testing
- HS-10502 + NHA, HS-10502 + HS-20093, HS-10502+ Apatinib
- Where
- China
- Volunteers
- 157 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Colorectal Cancer Metastatic, Triple Negative Breast Cancer
A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
This study is being conducted to assess the safety, tolerability, and efficacy of EDP1503 alone and in combination with pembrolizumab in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, and…
- Conditions
- Colorectal Cancer Metastatic, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Bladder Cancer
- Trial name
- NCT03775850
- Testing
- EDP1503, Pembrolizumab
- Where
- 8 sites in United States, Canada
- Volunteers
- 69 people
- Sponsor
- Evelo Biosciences, Inc.
HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer, HER2-negative Circulating Tumor Cells
DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
Several studies have indicated that determining prevalence and number of circulating tumor cells (CTCs) at various time points during treatment may be an effective tool for assessing treatment efficacy in metastatic breast cancer…
- Conditions
- HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer, HER2-negative Circulating Tumor Cells, Postmenopausal Female Patients
- Trial name
- NCT02035813
- Testing
- Ribociclib, Eribulin
- Where
- Germany
- Volunteers
- 116 people
- Sponsor
- Prof. Wolfgang Janni
Breast Cancer
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
The over-arching goal of the Contrast-Enhanced Spectral Mammography Imaging Screening Trial (CMIST) is to determine if dual-energy contrast-enhanced spectral mammography (CESM) can detect more cancers with fewer false positives…
- Trial name
- CMIST (NCT05625659)
- Testing
- Dual-Energy Contrast-Enhanced Spectral Mammography (CESM)
- Where
- 13 sites in United States, Canada
- Volunteers
- 2,032 people, healthy volunteers welcome
- Sponsor
- American College of Radiology
Breast Cancer
Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00103233
- Testing
- trastuzumab, vinorelbine tartrate
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
Safety Study of the Hypo-fractionated (Large Doses) Radiation Therapy in Post-menopausal Women With Breast Cancers
The purpose of this study is to determine whether high dose of radiation therapy (RT) are effective over standard 6-week radiation treatment in patients with breast cancer
- Trial name
- NCT02883985
- Testing
- 6 Gy/ fraction
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- NYU Langone Health
Locally Advanced or Metastatic Solid Tumor
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with carboplatin designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in participants with advanced or metastatic…
- Trial name
- NCT03717415
- Testing
- Rebastinib, Carboplatin
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Neuropathic Pain, Chemotherapy Effect
Prevention of Paclitaxel-induced Neuropathic Pain in Patients With Planned Paclitaxel Chemotherapy (PrevTel)
Phase IIa clinical trial will be conducted with patients requiring in-label paclitaxel-chemotherapy due to ovarian or breast cancer.
- Trial name
- PrevTel (NCT05322889)
- Testing
- Telmisartan tablets
- Where
- Germany
- Volunteers
- 35 people
- Sponsor
- Dr. Frank Behrens
Breast Cancer, Chronic Myeloproliferative Disorders
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
RATIONALE: Antifungals such as ravuconazole may be effective in preventing fungal infections in patients undergoing chemotherapy and stem cell transplantation.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection
- Trial name
- NCT00064311
- Testing
- ravuconazole
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Breast Cancer
Development and Assessment of the 8-item Chronic Pain Acceptance Questionnaire to Measure Disease Acceptance in Women With Breast Cancer
This observational study was conducted to develop and test a new self-report questionnaire, the Cancer Pathology Acceptance Questionnaire for Breast Cancer (CPAQ-8-BC), specifically adapted for women diagnosed with Breast Cancer…
- Trial name
- CPAQ-8-BC (NCT07328321)
- Testing
- Cancer Pathology Acceptance Questionnaire
- Where
- Italy
- Volunteers
- 101 people
- Sponsor
- G. d'Annunzio University
Breast Cancer, Hot Flashes
Citalopram in Treating Postmenopausal Women With Hot Flashes
RATIONALE: Citalopram may help relieve hot flashes in women who had or have not had breast cancer. It is not yet known which dose of citalopram is more effective in treating hot flashes in postmenopausal women.
- Conditions
- Breast Cancer, Hot Flashes, Psychosocial Effects of Cancer and Its Treatment
- Trial name
- NCT00363909
- Testing
- citalopram hydrobromide
- Where
- 198 sites in United States
- Volunteers
- 254 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Ovarian Cancer, Breast Cancer
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
The rationale of the ROSY-O study is to continue to provide study treatment for patients who have participated in a parent study with olaparib and who are continuing to derive clinical benefit from treatment at the end of such…
- Trial name
- ROSY-O (NCT04421963)
- Testing
- Olaparib
- Where
- 107 sites in United States, Belgium and 21 more
- Volunteers
- 185 people
- Sponsor
- AstraZeneca
Breast Cancer, Medication Adherence
SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors
The purpose of this study is to determine whether weekly SMS reminders are effective in improving medication adherence of adjuvant aromatase inhibitors in women with breast cancer.
- Trial name
- NCT02524548
- Testing
- SMS reminder
- Where
- 2 sites in Singapore
- Volunteers
- 244 people
- Sponsor
- National University of Singapore
Advanced Breast Cancer
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
The purpose of this study is to assess the safety and efficacy of alpelisib plus fulvestrant in men and postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor 2 (HER2)-negative, advanced breast…
- Trial name
- NCT04524000
- Testing
- Alpelisib, Fulvestrant
- Where
- 15 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane may fight breast cancer by reducing the production of estrogen.
- Trial name
- NCT00032136
- Testing
- exemestane, tamoxifen citrate, adjuvant therapy
- Where
- United Kingdom
- Volunteers
- 4,400 people
- Sponsor
- Cancer Research Campaign Clinical Trials Centre
Breast Neoplasm Female, Fertility Preservation
Web-based Oncofertility Support Tool for Reproductive-age Women With Breast Cancer
The aim of this study was to develop electronic systems (e-systems) for oncofertility support, and to examine the comprehensibility, feasibility, usability, and effects on social support and preparation for decision-making.
- Trial name
- NCT05100498
- Testing
- Web-based oncofertility support tool
- Where
- Taiwan
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Mackay Medical College
Breast Carcinoma
E-Health Support Program (PACK Health Program) in Supporting Patient Reported Symptoms in Newly Diagnosed Patients With Breast Cancer
This trial studies how well an electronic (e)-health support program, called the PACK Health Program, supports patient reported symptoms in newly diagnosed patients with breast cancer.
- Trial name
- NCT05549687
- Testing
- Questionnaire Administration, Supportive Care
- Where
- United States
- Volunteers
- 419 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced/Metastatic Solid Tumors
Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors
Phase I, first-in-human, open-label, multicenter, dose-escalation and dose expansion study with the aim of exploring safety, tolerability and preliminary antitumor activity of NMS-03305293 (a PARP inhibitor) as single agent in…
- Trial name
- NCT04182516
- Testing
- NMS-03305293
- Where
- 10 sites in United States, Bulgaria and 3 more
- Volunteers
- 52 people
- Sponsor
- Nerviano Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.